Open Trial of Mirtazapine in Patients with Fibromyalgia

Background: Some positive therapeutic effects in fibromyalgia syndrome (FS) were reported with both tricyclic and new antidepressant drugs as well as serotonergic agents (5HT2 and 5HT3 receptor blockers).
Methods: In the present study, a novel antidepressant drug mirtazapine, 15-30 mg/day, has been used in 29 patients with FS in an open trial.
Results: Twenty-six patients completed the six-week study. Ten (38 %) were considered responders on account of the reduction of ≥ 40 % on pain, fatigue and sleep disturbances and remission of depressive symptoms at the end of study. Eighteen patients had at least moderate depression before mirtazapine treatment and 8 patients presented mild depressive symptoms. Reduction on main symptoms of FS after 6 weeks of mirtazapine treatment significantly correlated with the reduction in depression. However, the percentage of responders and patients with ≥ 40 % reduction on main symptoms of fibromyalgia was similar in high and low depression groups.
Conclusions: The results obtained suggest that mirtazapine may be promising method of FS treatment. Further double-blind placebo-controlled studies are required to confirm these results.

References

• 1 Alnigenis M N, Barland P. Fibromyalgia syndrome and serotonin.  Clin Exp Rheumatol. 2001;  19 205-210
• 2 Anderberg U M, Marteinsdottir I, von Knorring L. Citalopram in patients with fibromyalgia - a randomized, double-blind, placebo-controlled study.  Eur J Pain. 2000;  4 27-35
• 3 Arnold L M, Hess E V, Hudson J I, Welge J A, Berno S EE, Keck PE J r. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgi.  Am J Med. 2002;  112 237-239
• 4 Beck A T, Ward C H, Mendelsohn M. An inventory for measuring depression.  Arch Gen Psychiatry. 1961;  4 561-571
• 5 Burckhardt C S, O’Reilly C O, Wiens A N, Clark S R, Campbell A M, Bennett R M. Assessing depression in fibromyalgia patients.  Arthritis Care Res. 1994;  7 35-39
• 6 Den Boer T. The effect of mirtazapine on central noradrenergic and serotonergic neurotransmission.  Int Clin Psychopharmacol. 1995;  10 (suppl 4) 19-23
• 7 Dwight M M, Arnold L M, O’Brien H, Metzger R, Morris-Park E, Keck P E. An open trial of venlafaxine treatment of fibromyalgia.  Psychosomatics. 1998;  39 14-17
• 8 Hamilton M. A rating scale for depression.  J Neurol Neurosurg Psychiatry. 1960;  23 6-62
• 9 Heymann R E, Helfenstein M, Feldman D. A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures.  Clin Exp Rheumatol. 2001;  19 697-702
• 10 Huskisson E C. Measurement of pain.  Lancet. 1974;  2 1127-1131
• 11 Klein R, Bänsch M, Berg P A. Clinical relevance of antibodies against serotonin and gangliosides in patients with primary fibromyalgia syndrome.  Psychoneuroendocrinology. 1992;  17 593-598
• 12 Kraus T, Haack M, Schuld A, Hinze-Selch D, Koethe D, Pollmacher T. Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine.  Pharmacopsychiatry. 2002;  35 220-225
• 13 Kudoh A, Katagai H, Takazawa T. Current perception thresholds of patients with long-term administration of maprotiline.  Pharmacopsychiatry. 2003;  36 57-60
• 14 Roizenblatt S, Moldofsky H, Benedito-Silva A A, Tufik S. Alpha sleep characteristic in fibromyalgia.  Arthritis Rheum. 2001;  44 222-230
• 15 Samborski W, Stratz T, Kretzmann W M, Mennet P, Müller W. Vergleichende Untersuchungen über das Vorkommen vegetativer und funktioneller Beschwerden bei Lumbalgien und generalisierten Tendomyopathien.  Z Rheumatol. 1991;  50 378-381